STADA Strengthens Market Position with Growth in 2025

Tashkent, Uzbekistan (UzDaily.com) — In 2025, STADA continued successfully executing its strategy across three core segments: consumer healthcare, generics, and specialty medicines, including innovative pharmaceuticals.

The company’s adjusted revenue in constant currency rose by 6%, reaching €4.3 billion, while adjusted EBITDA increased by 8% to €961 million. Growth was contributed by all regions of presence — Western, Central, and Eastern Europe, Germany, the Middle East, and Asia. Key drivers included successful launches across all three segments and licensing of 110 new products, strengthening the company’s development portfolio.

The specialty medicines segment saw revenue grow 17%, surpassing €1 billion and accounting for nearly a quarter of total revenue. Growth was driven by biosimilars and innovative treatments. Sales of Uzpruvo (ustekinumab) continued double-digit growth across more than 20 markets, expanding coverage in bone, immunology, and oncology therapies. New biosimilars, including golimumab and tocilizumab, are planned for launch in 2026.

Innovative medicines also expanded patient access to effective therapies in nephrology and neurology. Kinpeygo achieved strong growth due to expanded indications for patients with the rare kidney disease IgAN and inclusion in KDIGO guidelines. In neurology, the infusion pump Lecigon broadened access for late-stage Parkinson’s patients, and the apomorphine therapy ONAPGO was launched in the U.S. Oncology offerings in the specialty segment were supplemented with nilotinib and paclitaxel albumin.

The generics segment grew 5% on an adjusted basis, outpacing the European market, driven by rivaroxaban, cardiology products, and portfolio gap-filling in local markets. Consumer healthcare revenue increased 2% despite a mild cold and flu season. Key brands Nizoral, Levomecol, Cetraben, Elotrans, Protectis, Eunova, Walmark, and Natures Aid all recorded steady growth. E-commerce sales nearly doubled between 2022 and 2025, supported by digital channels and AI initiatives.

STADA continues to explore global acquisition opportunities in consumer healthcare and is building a portfolio of innovative drugs, including oncology and cardiology molecules, as well as blockbusters for diabetes and obesity treatment.

CEO Peter Goldschmidt emphasized that STADA’s success stems not only from its product portfolio but also its corporate culture. High employee engagement across nearly 12,000 staff worldwide, including production facilities, underpins sustainable growth and the company’s mission to care for people’s health as a reliable partner.

STADA Arzneimittel AG, headquartered in Bad Vilbel, Germany, sells products in over 100 countries. At the end of 2025, the company employed 11,749 people, generating revenue of €4.296 billion with an adjusted EBITDA of €961 million.